Pall signs Japanese deal for blood screen technology:
This article was originally published in Clinica
Executive Summary
Kawasumi Laboratories of Tokyo is to distribute Pall's eBDS (enhanced Bacterial Detection System) in Japan. Under the exclusive deal, Kawasumi will also be responsible for obtaining Japanese regulatory approval for the technology, which received US FDA clearance in January 2004. eBDS can detect bacteria in platelets derived both from single donors and random donor collection and automatically provide pass/fail results in 30 seconds. Bacteria contaminate between one in 2,000 and one in 5,000 platelets collected worldwide, says Pall. There are about 780,000 platelet collections in Japan every year.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.